Pharmaceutical giants Merck (MRK) and Eli Lilly (LLY) are scheduled to report third-quarter results on October 29, with analysts expecting a year-on-year earnings decline in both cases.
Merckâs per share earnings are projected to drop 19% to $2.09, while Eli To ensure this doesnât happen in the future, please enable Javascript and cookies in your browser
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. Entering text into the input field will update the search result below Quick Insights Merck faces a patent cliff and potential slowing of Keytrudaâs U.S. sales growth, with added pressure from new formulations, changes in specialty pharmacy purchases, and lower-than-anticipated generic competition.
Eli Lillyâs revenue growth is mainly due to its weight-loss and obesity franchise, blockbuster drugs like Mounjaro, Zepbound, and new developments such as the oral GLP-1 drug Foundayo and the pipeline drug Retatrutide, which drives significant investor focus. Eli Lilly faces pricing pressures, net price compression, strong competition in GLP-1/obesity market, and high valuation expectations that leave little room for errors in pipeline or operational execution